Abeona Therapeutics Stock Price, News & Analysis (NASDAQ:ABEO)

$11.60 -0.90 (-7.20 %)
(As of 02/21/2018 04:00 AM ET)
Previous Close$12.50
Today's Range$11.47 - $12.60
52-Week Range$4.55 - $22.75
Volume1.01 million shs
Average Volume1.18 million shs
Market Capitalization$542.59 million
P/E Ratio-17.85
Dividend YieldN/A
Beta1.36

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics logoAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ABEO
CUSIPN/A
Phone+1-214-9055100

Debt

Debt-to-Equity RatioN/A
Current Ratio22.20%
Quick Ratio22.20%

Price-To-Earnings

Trailing P/E Ratio-17.8461538461538
Forward P/E Ratio-19.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$890,000.00
Price / Sales609.72
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book4.68

Profitability

Trailing EPS($0.65)
Net Income$-21,870,000.00
Net Margins-2,946.58%
Return on Equity-27.69%
Return on Assets-25.32%

Miscellaneous

Employees19
Outstanding Shares46,780,000

Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its earnings results on Wednesday, November, 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. The biopharmaceutical company earned $0.22 million during the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. View Abeona Therapeutics' Earnings History.

When will Abeona Therapeutics make its next earnings announcement?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Abeona Therapeutics.

Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2018?

8 analysts have issued 12 month price objectives for Abeona Therapeutics' shares. Their predictions range from $15.00 to $35.00. On average, they expect Abeona Therapeutics' share price to reach $28.25 in the next twelve months. View Analyst Ratings for Abeona Therapeutics.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:

  • 1. Maxim Group analysts commented, "Abeona announced positive early data for ABO-101 in the first patient treated in the P1/2 trial for Sanfilippo Syndrome Type IIIB. As a reminder, this is the second gene therapy candidate targeting Sanfilippo Syndrome behind ABO-102, which has demonstrated positive data in 8 patients so far with Type IIIA disease. The difference between ABO-101 and ABO-102 is the replaced gene, same targeted pathway." (2/7/2018)
  • 2. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (11/23/2017)
  • 3. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
  • 4. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H. Rouhandeh, Executive Chairman of the Board (Age 61)
  • Timothy J. Miller Ph.D., President, Chief Executive Officer, Director (Age 45)
  • Jeffrey B. Davis, Chief Operating Officer (Age 54)
  • David P. Nowotnik Ph.D., Senior Vice President - Research and Development (Age 64)
  • Harrison G. Wehner III, Senior Vice President - Plasma
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary (Age 63)
  • Michelle Berg, Vice President - Communications & Operations
  • Andre'a Lucca, Vice President - Communications & Operations
  • Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
  • Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance

Who owns Abeona Therapeutics stock?

Abeona Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Viking Global Investors LP (8.64%), FMR LLC (8.35%), FMR LLC (8.35%), BlackRock Inc. (3.99%), Geode Capital Management LLC (0.59%) and EAM Investors LLC (0.47%). View Institutional Ownership Trends for Abeona Therapeutics.

Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?

Abeona Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Royce & Associates LP, Perceptive Advisors LLC, Goldman Sachs Group Inc., Kavi Asset Management LP, IFP Advisors Inc, Ardsley Advisory Partners and Brandywine Global Investment Management LLC. View Insider Buying and Selling for Abeona Therapeutics.

Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?

Abeona Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, BlackRock Inc., Sphera Funds Management LTD., J. Goldman & Co LP, Bank of New York Mellon Corp, EAM Investors LLC, Swiss National Bank and Alkeon Capital Management LLC. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of Abeona Therapeutics stock can currently be purchased for approximately $11.60.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $542.59 million and generates $890,000.00 in revenue each year. The biopharmaceutical company earns $-21,870,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Abeona Therapeutics employs 19 workers across the globe.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 Lee Pkwy Ste 600, DALLAS, TX 75219-5117, United States. The biopharmaceutical company can be reached via phone at +1-214-9055100 or via email at [email protected]


MarketBeat Community Rating for Abeona Therapeutics (ABEO)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abeona Therapeutics (NASDAQ:ABEO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.25$27.00$27.00$19.17
Price Target Upside: 56.08% upside56.07% upside67.18% upside119.05% upside

Abeona Therapeutics (NASDAQ:ABEO) Consensus Price Target History

Price Target History for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightSet Price TargetBuy$30.00HighView Rating Details
2/7/2018Maxim GroupReiterated RatingBuy$35.00HighView Rating Details
1/24/2018Royal Bank of CanadaReiterated RatingBuy$26.00LowView Rating Details
11/22/2017Jefferies GroupReiterated RatingBuy$28.00N/AView Rating Details
11/8/2017SunTrust BanksInitiated CoverageBuy$26.00N/AView Rating Details
10/11/2017Cantor FitzgeraldBoost Price TargetOverweight$21.00 -> $34.00N/AView Rating Details
10/10/2017CitigroupInitiated CoverageBuy$32.00N/AView Rating Details
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Abeona Therapeutics (NASDAQ:ABEO) Earnings History and Estimates Chart

Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ ABEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
11/15/2017Q3 2017($0.19)($0.13)$0.22 million$0.22 millionViewN/AView Earnings Details
8/15/2017Q2 2017($0.14)($0.21)$0.21 million$0.22 millionViewN/AView Earnings Details
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.11)($0.17)$0.30 million$0.24 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
11/17/2015Q3 2015($0.11)($0.19)$0.33 million$0.29 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.10)($0.16)$0.15 million$0.28 millionViewN/AView Earnings Details
5/14/2015Q1 2015($0.10)$0.26 millionViewN/AView Earnings Details
11/14/2014Q3 2014($4.15)$0.24 millionViewN/AView Earnings Details
8/14/2014Q2 2014($3.00)$0.25 millionViewN/AView Earnings Details
5/12/2014Q1 2014($4.00)$0.21 millionViewN/AView Earnings Details
3/26/2014Q4 2013($3.50)$0.16 millionViewN/AView Earnings Details
11/14/2013Q3 2013($2.00)$0.19 millionViewN/AView Earnings Details
8/14/2013Q2 2013($5.50)$0.47 millionViewN/AView Earnings Details
5/16/2013Q1 2013($2.50)$1.22 millionViewN/AView Earnings Details
3/19/2013Q4 2012($4.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($3.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($4.40)ViewN/AView Earnings Details
5/15/2012Q1 2012($4.00)($2.70)ViewN/AView Earnings Details
3/23/2012Q4 2011($2.80)ViewN/AView Earnings Details
11/14/2011Q3 2011($7.50)($3.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($7.85)ViewN/AView Earnings Details
5/16/2011Q1 2011($7.50)($7.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Abeona Therapeutics (NASDAQ:ABEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.14)($0.14)($0.14)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Abeona Therapeutics (NASDAQ ABEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 52.07%
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ ABEO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.0075,000View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abeona Therapeutics (NASDAQ ABEO) News Headlines

Source:
DateHeadline
Global Gene Therapy Market Expected to Reach $4,402 Million by 2023 - Allied Market ResearchGlobal Gene Therapy Market Expected to Reach $4,402 Million by 2023 - Allied Market Research
www.prnewswire.com - February 16 at 9:30 AM
Abeona Therapeutics (ABEO) Reports FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten DiseaseAbeona Therapeutics (ABEO) Reports FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
www.streetinsider.com - February 13 at 3:20 PM
BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In NewbornsBRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns
www.reuters.com - February 13 at 3:20 PM
Abeona Therapeutics (ABEO) A Global Phase 1/2 Clinical Trial Of Systemic Gene Transfer of scAAV9.U1a.hSGSH For MPS IIIA - SlideshowAbeona Therapeutics (ABEO) A Global Phase 1/2 Clinical Trial Of Systemic Gene Transfer of scAAV9.U1a.hSGSH For MPS IIIA - Slideshow
seekingalpha.com - February 13 at 3:20 PM
Abeona Therapeutics Receives FDA Orphan Drug Designation for ... - GlobeNewswire (press release)Abeona Therapeutics Receives FDA Orphan Drug Designation for ... - GlobeNewswire (press release)
globenewswire.com - February 12 at 3:20 PM
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten DiseaseAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
finance.yahoo.com - February 12 at 3:20 PM
Abeona Therapeutics: Data Update - Part 2 - Seeking AlphaAbeona Therapeutics: Data Update - Part 2 - Seeking Alpha
seekingalpha.com - February 12 at 5:55 AM
Form 8-K ABEONA THERAPEUTICS INC. For: Feb 09 - StreetInsider.comForm 8-K ABEONA THERAPEUTICS INC. For: Feb 09 - StreetInsider.com
www.streetinsider.com - February 11 at 6:01 AM
$240,000.00 in Sales Expected for Abeona Therapeutics Inc (ABEO) This Quarter$240,000.00 in Sales Expected for Abeona Therapeutics Inc (ABEO) This Quarter
www.americanbankingnews.com - February 11 at 2:28 AM
Abeona Therapeutics Inc (ABEO) Receives Consensus Recommendation of "Buy" from BrokeragesAbeona Therapeutics Inc (ABEO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 10 at 1:38 PM
Abeona Therapeutics (ABEO) Announces Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIAAbeona Therapeutics (ABEO) Announces Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
www.streetinsider.com - February 10 at 6:07 AM
Abeona Therapeutics (ABEO) PT Set at $30.00 by HC WainwrightAbeona Therapeutics (ABEO) PT Set at $30.00 by HC Wainwright
www.americanbankingnews.com - February 8 at 9:28 PM
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA - GlobeNewswire (press release)Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:20 PM
This ROTY Contender Just Released Promising Data - Seeking AlphaThis ROTY Contender Just Released Promising Data - Seeking Alpha
seekingalpha.com - February 8 at 5:47 AM
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial - GlobeNewswire (press release)Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:47 AM
Traders Need to Adapt to a New RealityTraders Need to Adapt to a New Reality
finance.yahoo.com - February 8 at 5:47 AM
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical TrialAbeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
finance.yahoo.com - February 8 at 5:47 AM
Why Abeona Therapeutics Jumped 14% on WednesdayWhy Abeona Therapeutics Jumped 14% on Wednesday
finance.yahoo.com - February 8 at 5:47 AM
Abeona Therapeutics (ABEO) Receives "Buy" Rating from Maxim GroupAbeona Therapeutics (ABEO) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - February 8 at 12:14 AM
Abeona Therapeutics (ABEO) Upgraded by BidaskClub to "Hold"Abeona Therapeutics (ABEO) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 3 at 9:18 PM
Stock Traders Buy High Volume of Abeona Therapeutics Call Options (ABEO)Stock Traders Buy High Volume of Abeona Therapeutics Call Options (ABEO)
www.americanbankingnews.com - February 3 at 1:26 AM
Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposiumAbeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
finance.yahoo.com - February 2 at 3:21 PM
Your Daily Pharma Scoop: Abeonas EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results - Seeking AlphaYour Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results - Seeking Alpha
seekingalpha.com - January 31 at 3:19 PM
Solid Biosciences slips on potential AAV toxicity - Seeking AlphaSolid Biosciences slips on potential AAV toxicity - Seeking Alpha
seekingalpha.com - January 31 at 3:19 PM
Abeona Therapeutics Inc: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis BullosaAbeona Therapeutics Inc: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
www.finanznachrichten.de - January 30 at 5:55 AM
Abeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis BullosaAbeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
www.streetinsider.com - January 30 at 5:55 AM
Abeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis Bullosa - StreetInsider.comAbeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis Bullosa - StreetInsider.com
www.streetinsider.com - January 29 at 3:20 PM
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis BullosaAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
finance.yahoo.com - January 29 at 3:20 PM
UPDATE: Abeona shares rise 10% on regenerative medicine advanced therapy designation from FDAUPDATE: Abeona shares rise 10% on 'regenerative medicine advanced therapy' designation from FDA
finance.yahoo.com - January 29 at 3:20 PM
Abeona Therapeutics (ABEO) "Buy" Rating Reiterated at Royal Bank of CanadaAbeona Therapeutics' (ABEO) "Buy" Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - January 28 at 4:30 PM
Abeona Therapeutics: Continued Upside In 2018 - Seeking AlphaAbeona Therapeutics: Continued Upside In 2018 - Seeking Alpha
seekingalpha.com - January 26 at 5:53 AM
-$0.13 EPS Expected for Abeona Therapeutics Inc (ABEO) This Quarter-$0.13 EPS Expected for Abeona Therapeutics Inc (ABEO) This Quarter
www.americanbankingnews.com - January 23 at 11:06 PM
Commit To Purchase Abeona Therapeutics At $12.50, Earn 16.4% Annualized Using Options - NasdaqCommit To Purchase Abeona Therapeutics At $12.50, Earn 16.4% Annualized Using Options - Nasdaq
www.nasdaq.com - January 23 at 3:23 PM
2018 Could Be Another Solid Year For Abeona Therapeutics - Seeking Alpha2018 Could Be Another Solid Year For Abeona Therapeutics - Seeking Alpha
seekingalpha.com - January 18 at 6:59 PM
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst - Seeking AlphaAbeona Therapeutics: The Upcoming Neurocognitive Catalyst - Seeking Alpha
seekingalpha.com - January 17 at 3:42 PM
Abeona Therapeutics Inc (ABEO) Given Consensus Recommendation of "Buy" by BrokeragesAbeona Therapeutics Inc (ABEO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 1:40 PM
Abeona Therapeutics Inc (ABEO) Short Interest UpdateAbeona Therapeutics Inc (ABEO) Short Interest Update
www.americanbankingnews.com - January 12 at 2:00 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - January 2 at 4:02 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - January 2 at 10:44 AM
Abeona Therapeutics (ABEO) Stock Rating Lowered by ValuEngineAbeona Therapeutics (ABEO) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 30 at 11:18 AM
ETFs with exposure to Abeona Therapeutics, Inc. : December 28, 2017ETFs with exposure to Abeona Therapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 1:51 PM
Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 10:22 AM
Abeona Therapeutics Inc (ABEO) Expected to Post Quarterly Sales of $240,000.00Abeona Therapeutics Inc (ABEO) Expected to Post Quarterly Sales of $240,000.00
www.americanbankingnews.com - December 23 at 9:44 AM
Abeona Therapeutics Inc (ABEO) Given Average Recommendation of "Buy" by AnalystsAbeona Therapeutics Inc (ABEO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 2:18 PM
Form 4 ABEONA THERAPEUTICS INC. For: Dec 14 Filed by: Alvino Mark - StreetInsider.comForm 4 ABEONA THERAPEUTICS INC. For: Dec 14 Filed by: Alvino Mark - StreetInsider.com
www.streetinsider.com - December 20 at 3:41 PM
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB - GlobeNewswire (press release)Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB - GlobeNewswire (press release)
globenewswire.com - December 20 at 3:41 PM
Abeona Therapeutics (ABEO) Reports Enrollment of First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIBAbeona Therapeutics (ABEO) Reports Enrollment of First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
www.streetinsider.com - December 20 at 10:59 AM
Financial Contrast: Durata Therapeutics (DRTX) versus Abeona Therapeutics (ABEO)Financial Contrast: Durata Therapeutics (DRTX) versus Abeona Therapeutics (ABEO)
www.americanbankingnews.com - December 13 at 8:48 AM
Biotech Stocks Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health - PR Newswire (press release)Biotech Stocks' Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health - PR Newswire (press release)
www.prnewswire.com - December 9 at 3:43 PM
Adverum: Preparing For Liftoff. The Next Abeona - Seeking AlphaAdverum: Preparing For Liftoff. The Next Abeona - Seeking Alpha
seekingalpha.com - December 7 at 3:48 PM

SEC Filings

Abeona Therapeutics (NASDAQ:ABEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abeona Therapeutics (NASDAQ:ABEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abeona Therapeutics (NASDAQ ABEO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.